Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

The Need to Avoid a Regulatory Gray Zone in Digital Wellness

4 August 2026 · By · Wire by Fusion42

Published

4 August 2026

Topic

regulatory

◆ Sectors

Digital Health

◆ Geography

United States

◆ Source

Read at jamanetwork.com →

◆ Verified

Fusion42 · 1 September 2026 · Fusion42 review

The US FDA's 2026 guidance excludes many low-risk digital wellness products from medical device regulation if they do not claim to diagnose or treat diseases, creating a regulatory gray zone for digital health technologies.

This Wire brief sits within Fusion42's coverage of Digital Health.

◆ ◆ The Wire takeaway

Your digital health product risks falling outside FDA oversight if it avoids direct disease claims, opening market access but raising legal ambiguity. Act now to clarify claims or engage with regulators before investing heavily.

◆ Coverage

1 source · 4 Aug 2026

◆ Related on Wire

◆ Topics

Digital Healthdigital-healthregulationFDAwellness-appsmedical-device